Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Robatel S, Hillen H, Mutisheva I, Müller JC, Wartenberg M, Ma F, Bäriswyl L, Evenepoel J, Scheele CLGJ, Lee DJ, Modlin RL, Kessler U, Nobis[...]

Roberts AM, Jeong C, Chou P, Ma EJ, Katz A, Yan MJ, Johnsen N, Nong Y, Armstrong AW. Association between out-of-pocket costs and treatment patterns[...]

Issa T, Klomhaus AM, Kasakevich C, Pickford J, Goh C. Central centrifugal cicatricial alopecia is associated with longer time to diagnosis among scarring alopecias. JAAD[...]